Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 401–500 of 2,039
Lv, X., Wang, H., Chen, C., Zhao, Y., Li, K., Wang, Y., Wang, L., Fu, S., & Liu, J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s443396 · Cited by 33
Abdrabou Abouelmagd, A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., Abuklish, D. M., & Belal, M. M. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2456441 · Cited by 25
The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Anala, A. D., Saifudeen, I. S. H., Ibrahim, M., Nanda, M., Naaz, N., & Atkin, S. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144575 · Cited by 39
Mullins, G. R., Hodsdon, M. E., Li, Y. G., Anglin, G., Urva, S., Schneck, K. B., Bardos, J. N., Martins, R. F., Brown, K. E., & Calderón, B. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad532 · Cited by 29
Self-citationObesity medications: A narrative review of current and emerging agents
Qi, Q., Cox, A., McNeil, S. E., & Sumithran, P. (2024) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2024.100472 · Cited by 41
Karakus, K. E., Klein, M. P., Aktürk, H. K., & Shah, V. N. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01592-9 · Cited by 30
“Tirzepatide is a once-weekly dual agonist to glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors which is currently FDA-approved for the treatment of type 2 diabetes and obesity [1].”
BackgroundA real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
Liu, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1397029 · Cited by 37
Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis
Park, S., Jain, R., & Mirfakhraee, S. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.08.005 · Cited by 26
Comprehensive treatment of diabetic endothelial dysfunction based on pathophysiological mechanism
Liu, Z., Lu, J., Sha, W., & Lei, T. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1509884 · Cited by 44
“In a study conducted by Frías et al. (95), tirzepatide, which functions as a dual glucose-dependent insulinotropic polypeptide and GLP-1R agonist, exhibited a favorable impact on glucose homeostasis and was associated with a relatively rapid and pronounced antihypertensive effect.”
Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists
Chen, J., Cooper, M., & Coughlan, M. T. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101641 · Cited by 35
Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
Colin, I. M., & Gérard, A.-C. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.35 · Cited by 30
“Compared with liraglutide, semaglutide appears to have better uptake in the brain, which may explain its greater efficacy in weight control and in reducing energy intake (by twice that measured with liraglutide: 35% versus 16%).33 The decision to approve this new medication was taken by the EMA in November 2021 (after…”
BackgroundInfluentialEffects of treatment for diabetes mellitus on testosterone concentrations: A systematic review
Cauwenberghe, J. V., Block, C. E. M. D., Vanderschueren, D., & Antonio, L. (2022) · Andrology · doi:10.1111/andr.13318 · Cited by 26
Emerging drugs for the treatment of diabetic nephropathy
Kim, Y. K., Ning, X., Munir, K. M., & Davis, S. N. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2155632 · Cited by 26
“Tirzepatide, a recently FDA-approved dual GLP-1/GIP agonist, has shown promising data regarding glycemic control and weight loss benefits, even when compared to a GLP-1 receptor agonist [40,41].”
BackgroundAn Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal
Enright, C., Thomas, E., & Saxon, D. R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac195 · Cited by 32
“SURPASS-2 compared the same doses of tirzepatide (5 mg, 10 mg, 15 mg) with semaglutide 1.0 mg weekly, finding more effective and dose-dependent reductions in body weight, blood pressure, and hemoglobin A1C [85].”
InfluentialNewer pharmacological interventions directed at gut hormones for obesity
Camilleri, M., & Acosta, A. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16278 · Cited by 29
Wu, W., Tong, H.-M., Li, Y., & Cui, J. (2023) · Endocrine · doi:10.1007/s12020-023-03636-9 · Cited by 30
Sachs, S., Götz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01940-2 · Cited by 24
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
To do one and to get more: Part I. Diabetes and bone
Lee, W.-L., Wang, P., Yang, S., Liu, C., Chang, W.-H., & Lee, F. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000803 · Cited by 25
Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management
Powell, J., & Taylor, J. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.12.014 · Cited by 27
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 29
Self-citationEffects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice
Lv, F., Cai, X., Lin, C., Yang, W., & Ji, L. (2024) · Pharmaceuticals · doi:10.3390/ph17121655 · Cited by 26
Holst, J. J., Jepsen, S. L., & Modvig, I. M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102189 · Cited by 29
Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities
Aboolian, A., Urner, S., Roden, M., Jha, J. C., & Jandeleit-Dahm, K. A. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_576 · Cited by 28
Matza, L. S., Stewart, K. D., Landó, L. F., Patel, H., & Boye, K. S. (2022) · Patient · doi:10.1007/s40271-022-00578-8 · Cited by 31
“Like most exit interview studies, this research was conducted in a small subset of 27 patients who had completed the SURPASS-2 trial (N = 1879 [12]) and one patient who had completed SURPASS-3 (N = 1444 [13]).”
BackgroundMethodResultInfluentialSelf-citationGuan, R., Yang, Q., Yang, X., Du, W., Li, X., & Ma, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.998816 · Cited by 27
“After further selection (Figure 1), eight unique RCTs fulfilled the inclusion criteria (Frias et al., 2018; Frias et al., 2020; Del Prato et al., 2021; Frías et al., 2021; Ludvik et al., 2021; Rosenstock et al., 2021; Dahl et al., 2022; Inagaki et al., 2022).”
BackgroundMethodGariani, K., & Putzu, A. (2024) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000001914 · Cited by 31
Epithelial metabolism as a rheostat for intestinal inflammation and malignancy
Schwärzler, J., Mayr, L., Grabherr, F., Tilg, H., & Adolph, T. E. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.01.004 · Cited by 25
The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Kagdi, S., Lyons, S. A., & Beaudry, J. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0361 · Cited by 33
Au, H. C. T., Zheng, Y. J., Le, G. H., Wong, S., Phan, L., Teopiz, K. M., Kwan, A. T. H., Rhee, T. G., Rosenblat, J. D., Ho, R., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.11.019 · Cited by 31
The (dys)regulation of energy storage in obesity
Levin, B. E., Geary, N., & Lutz, T. A. (2025) · Physiological Reviews · doi:10.1152/physrev.00002.2024 · Cited by 29
Delvadia, P., Dhote, V. V., Mandloi, A. S., Soni, R., & Shah, J. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00729 · Cited by 29
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 29
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 28
Lewis, G. F., & Hegele, R. A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00284-9 · Cited by 27
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 26
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
A systematic review of the association of Type I diabetes with sensorineural hearing loss
Mittal, R., McKenna, K., Keith, G., Lemos, J. R. N., Mittal, J., & Hirani, K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298457 · Cited by 28
The antiemetic actions of GIP receptor agonism
Borner, T., Jonghe, B. C. D., & Hayes, M. R. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00330.2023 · Cited by 28
Holst, J. J. (2021) · Diabetes · doi:10.2337/dbi21-0026 · Cited by 23
Preventing new-onset heart failure: Intervening at stage A
Upadhya, B., Hegde, S., Tannu, M., Stacey, R. B., Kalogeropoulos, A. P., & Schocken, D. D. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100609 · Cited by 27
“Recent studies showed that tirze-patide was superior to semaglutide and insulin degludec in decreasing HBAIc and body weight [113,114].”
BackgroundThe GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines
Douros, J. D., Mokrosiński, J., & Finan, B. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0226 · Cited by 31
Female obesity: clinical and psychological assessment toward the best treatment
Guglielmi, V., Grave, R. D., Leonetti, F., & Solini, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1349794 · Cited by 44
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
Nicze, M., Dec, A., Borówka, M., Krzyżak, D., Bołdys, A., Bułdak, Ł., & Okopień, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158202 · Cited by 33
Ostrominski, J. W., Ortega-Montiel, J., Tesfaye, H., ALIX, C., DiCesare, E., CROMER, S. J., Wexler, D. J., Paik, J. M., & Patorno, E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02870 · Cited by 29
Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G. D., Monda, M., & Marra, M. L. (2025) · Healthcare · doi:10.3390/healthcare13121437 · Cited by 37
Novel approaches to hypoglycemia and burnt-out diabetes in chronic kidney disease
Rhee, C. M., Kalantar‐Zadeh, K., & Tuttle, K. R. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000756 · Cited by 27
Type 2 Diabetes Remission with Significant Weight Loss: Definition and Evidence-Based Interventions
Ko, J. H., & Kim, T. N. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22001 · Cited by 31
Pedersen, S. D., Giorgino, F., Umpierrez, G., Thieu, V. T., Rodríguez, A., Nicolay, C., Fernández Landó, L., Karanikas, C. A., & Kiljanski, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15140 · Cited by 22
Self-citationEffects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review
Viggers, R., Rasmussen, N. H., & Vestergaard, P. (2023) · JBMR Plus · doi:10.1002/jbm4.10817 · Cited by 29
Baker, D. E., Walley, K., & Levien, T. L. (2023) · Hospital Pharmacy · doi:10.1177/00185787221125724 · Cited by 21
Raven, L. M., Brown, C., & Greenfield, J. R. (2024) · Medical Journal of Australia · doi:10.5694/mja2.52170 · Cited by 21
Structured lifestyle modification as an adjunct to obesity pharmacotherapy: there is much to learn
Murphy, E. E., & Finucane, F. M. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01499-2 · Cited by 23
GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
ROSENKILDE, M. M., Lindquist, P., Kizilkaya, H. S., & Gasbjerg, L. S. (2024) · Peptides · doi:10.1016/j.peptides.2024.171212 · Cited by 22
Liu, T., Zhou, L., Chen, Y., Lin, J., & Zhu, H. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001896 · Cited by 22
Amorim, R., Soares, P., Chavarria, D., Benfeito, S., Cagide, F., Teixeira, J., Oliveira, P. J., & Borges, F. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116723 · Cited by 26
An update on ocular effects of antidiabetic medications
Sadeghi, E., Rahmanipour, E., Valsecchi, N., Kapoor, S., Cicinelli, M. V., & Chhablani, J. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.01.010 · Cited by 23
Revolutionizing Diabetes Management Through Nanotechnology-Driven Smart Systems
Kaushal, A., Musafir, A., Sharma, G., Rani, S., Singh, R. K., Kumar, A., Bhadada, S. K., Barnwal, R. P., & Singh, G. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060777 · Cited by 33
“In addition, SUR-PASS trials suggest tirzepatide, a dual GIP/GLP-1 receptor agonist, shows greater reduction in HbA1c and body weight when compared to semaglutide and other typical GLP-1 receptor agonists [132].”
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
Smith, I., Hardy, E., Mitchell, S., & Batson, S. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s392952 · Cited by 39
Sun, L., Yuan, Y., Li, Y., & Rao, X. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11948 · Cited by 20
Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
Ma, Z., Jin, K., Yue, M., Chen, X., & Chen, J. (2023) · Journal of Diabetes Research · doi:10.1155/2023/5891532 · Cited by 29
“The incidence of gastrointestinal discomfort increased when the dose was increased, but frequently during the transitional phase [8].”
BackgroundResultInfluentialSalmen, T., Șerbănoiu, L. I., Bica, I.-C., Serafinceanu, C., Muzurović, E. M., Janež, A., Busnatu, Ș., Banach, M., Rizvi, A. A., Rizzo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119760 · Cited by 25
A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes
Feng, P., Sheng, X., Ji, Y., Urva, S., Wang, F., Miller, S., Qian, C., An, Z., & Cui, Y. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02536-8 · Cited by 27
Tsukamoto, S., Tanaka, S., Yamada, T., Uneda, K., Azushima, K., Kinguchi, S., Wakui, H., & Tamura, K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15312 · Cited by 28
Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
Imam, A. A., Alim, H., Binhussein, M., Kabli, A. F., Alhasnani, H., Allehyani, A., Aljohani, A. M., Mohorjy, A., Tawakul, A. A., Samannodi, M. S., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad129 · Cited by 23
Kang, Y. M., Punov, V., Lim, S., & Nauck, M. A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16398 · Cited by 20
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency
Bhatnagar, P., Ahmad, N. N., Li, X., Coghlan, M., Kaplan, L. M., & Farooqi, I. S. (2025) · Nature Medicine · doi:10.1038/s41591-025-03913-2 · Cited by 20
“%) in people with obesity, with and without type 2 diabetes 2,3 .”
Yang, J., Gu, Y., Chen, H., Wang, H., Hong, L., Li, B., & Yang, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1453825 · Cited by 26
Mather, K. J., Mari, A., Weerakkody, G. J., Heise, T., DeVries, J. H., Urva, S., Coşkun, T., Miličević, Z., Haupt, A., & Thomas, M. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16159 · Cited by 24
Zhang, Y., Xie, Y., Xia, S., Ge, X., Li, J., Liu, F., Jia, F., Wang, S., Zhou, Q., Gao, M., et al. (2025) · Advanced Science · doi:10.1002/advs.202411980 · Cited by 36
Billings, L. K., Winne, L., Sharma, P., Valderas, E. G., Chivukula, K. K., & Kwan, A. Y. M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03849 · Cited by 28
Colazo, J. M., Keech, M. C., Shah, V., Hoogenboezem, E. N., Lo, J. H.-J., Francini, N., Cassidy, N. T., Yu, F. Z., Sorets, A. G., McCune, J. T., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01376-x · Cited by 29
“Albumin is one of the most prominent proteins in synovial fluid (SF) 46,47 , and it also shows cartilage penetration, being 15-fold more concentrated in the deep layers of arthritic than healthy cartilage and having 2-fold higher penetration into human cartilage than IgG antibodies 28,29 .”
Tan, Y. W., Shang, M., Davis, S., & Gananadha, S. (2025) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-025-03831-4 · Cited by 24
“The adverse effect profiles of tirzepatide and semaglu - tide were found to be similar at lower doses, but the dropout rates increased at higher doses of tirzepatide (10 mg and 15 mg) compared to 5 mg [41].”
Glucagon‐like peptide‐1: Are its roles as endogenous hormone and therapeutic wizard congruent?
Holst, J. J. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13433 · Cited by 25
Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
Blüher, M., Ceriello, A., Davies, M., Rodbard, H., Sattar, N., Schnell, O., Tonchevska, E., & Giorgino, F. (2022) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.330 · Cited by 20
Self-citationPharmacological profile of once-weekly injectable semaglutide for chronic weight management
Lau, D. C. W., Batterham, R. L., & le Roux, C. W. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2070473 · Cited by 27
“5 kg [15 mg]); for both tirzepatide and semaglutide treatments, the most common AEs were gastrointestinal-related events [64].”
BackgroundLisco, G., Tullio, A. D., Disoteo, O., Geronimo, V. D., Piazzolla, G., Pergola, G. D., Giagulli, V. A., Jirillo, E., Guastamacchia, E., Sabbà, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.920541 · Cited by 25
“A head-to-head comparison between TZP and Semaglutide as an add-on to metformin in uncontrolled T2D was analyzed in the SURPASS-2 (35).”
MethodMudaliar, S. R. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-023-00357-w · Cited by 37
Zhang, X., & Marx, C. M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.3.276 · Cited by 24
Engineering bacteria to modulate host metabolism
Ciocan, D. M., & Elinav, E. (2023) · Acta Physiologica · doi:10.1111/apha.14001 · Cited by 22
Role of metformin in the management of type 2 diabetes: recent advances
Gonzalez-Lopez, C., & Wojeck, B. S. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16511 · Cited by 28
Camilleri, M. (2023) · Neurogastroenterology & Motility · doi:10.1111/nmo.14660 · Cited by 25
Anti-obesity pharmacotherapy in adults with chronic kidney disease
Taber-Hight, E., Gilmore, A. C., & Friedman, A. N. (2023) · Kidney International · doi:10.1016/j.kint.2023.10.014 · Cited by 22
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
Chatzianagnostou, K., Gaggini, M., Suman, A. F., Simonini, L., & Vassalle, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116218 · Cited by 23
Clontz, A. D., Gan, E., Hursting, S. D., & Bae-Jump, V. L. (2024) · Cancers · doi:10.3390/cancers16122197 · Cited by 25
“Moreover, certain weight loss medications have improved insulin sensitivity and metabolic parameters, thereby mitigating obesity-associated comorbidities, such as type 2 diabetes [26,27].”
BackgroundModern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Caturano, A., Galiero, R., Rocco, M. P., Tagliaferri, G., Piacevole, A., Nilo, D., Lorenzo, G. D., Sardu, C., Vetrano, E., Monda, M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092039 · Cited by 27
Obesity-induced neuronal senescence: Unraveling the pathophysiological links
Ghosh, P., Fontanella, R. A., Scisciola, L., Taktaz, F., Pesapane, A., Basilicata, M. G., Tortorella, G., Matacchione, G., Capuano, A., Vietri, M. T., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102533 · Cited by 25
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 25
“[56,57] Thus, sustained weight loss is crucial for reducing liver-related morbidity and mortality in SLD.”
BackgroundExperimental and Clinical Endocrinology & Diabetes
Hu, T. F. S. H. Y. C. Z. C. J. C. W. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-00000017 · Cited by 20
Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes
Heerspink, H. J. L., Friedman, A. N., Bjornstad, P., van Raalte, D. H., Cherney, D., Cao, D., Garcia-Pérez, L.-E., Stefanski, A., Turfanda, I., Bunck, M. C., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000764 · Cited by 20
“19 In people with type 2 diabetes at high cardiovascular risk, 104 weeks of treatment with tirzepatide was associated with reduced albuminuria and a slower decline in eGFR compared with treatment with insulin glargine.”
Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C. (2025) · Pharmaceuticals · doi:10.3390/ph18050668 · Cited by 19
Aamir, A. B., Latif, R., Alqoofi, J. F., Almarzoq, F. A., Fallatah, J. O., Hassan, G. A., & Saab, F. A. A. A. A. (2025) · Journal of Clinical Medicine Research · doi:10.14740/jocmr6231 · Cited by 19
The role of incretin receptor agonists in the treatment of obesity
Forst, T. M., Block, C. E. M. D., Prato, S. D., Armani, S., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15796 · Cited by 22
Self-citationAbsorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys
Martin, J. A., Czeskis, B. A., Urva, S., & Cassidy, K. C. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106895 · Cited by 26
Nassar, M., Nassar, O., Abosheaishaa, H. M., & Misra, A. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103116 · Cited by 30
Tian, Y., Tian, R., He, J., Guo, Y., Yan, P., Cheng, Y., Li, R., & Wang, B. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113877 · Cited by 26
Finan, B., Douros, J. D., Goldwater, R., Hansen, A. M. K., Hjerpsted, J., Hjøllund, K. R., Kankam, M. K., Knerr, P. J., Konkar, A. A., Mowery, S. A., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102129 · Cited by 21
“Tirze-patide, a single-molecule GLP-1R/glucose-dependent insulinotropic peptide receptor (GIPR) co-agonist with receptor activity favoring GIPR relative to GLP-1R, demonstrated greater body weight reduction and glycemic control in individuals with T2D than semaglutide [7].”
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 23
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.